Loading...
Loading...
Jefferies increases its price target from $56 to $57 on Health Care REIT
HCN on the company's growth, but reiterates its Hold rating on shares as this growth is acquisition-dependent.
Jefferies comments, "HCN remains an acquisition-fueled growth story, based on the thesis that HCN can successfully source and execute accretive off-market acquisition opportunities from its strong existing relationships with a diverse pool of regional operators. However, pricing on recent
acquisitions suggests off-market pricing may be converging quickly towards public auction pricing."
HCN closed at $55.99 on Wednesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in